Antisense oligonucleotides targeting cooperating oncogenes

Details Antisense oligonucleotides targeting cooperating oncogenes Antisense oligonucleotides targeting cooperating oncogenes

1994-09-15

1998-03-31

Guzo, David

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

514 44, C07H 2104

Patent

active

057340390

ABSTRACT:
Therapeutic combinations of two or more antisense oligonucleotides are provided. At least one first antisense oligonucleotide specific for a cytoplasmic oncogene or proto-oncogene and at least one second antisense oligonucleotide specific for a nuclear oncogene or proto-oncogene are combined for treatment of a neoplastic disease. The first antisense oligonucleotide may be specific for, e.g., a ras or raf gene, or an oncogene which codes for a protein tyrosine kinase. The nuclear gene-targeting antisense oligonucleotide preferably may be specific for a nuclear oncogene or proto-oncogene which encodes a transcriptional factor. The combined oligonucleotides have enhanced activity against neoplastic disease.

REFERENCES:
Morishita et al. (1994) J. Clin. Invest. 93:1458-1464.
Morishita et al. (1993) Proc. Natl. Acad. Sci. USA 90:8474-8478.
Genesis Report-Rx (1994) 3.
Hunter (1991) Cell 64:249-270.
Tidd et al. (1988) Anti-Cancer Drug Des. 3:117-127.
Amini et al. (1986) Mol. Cell. Bio. 6:2305-2316.
Heikkila et al. (1987) Nature 328:445-449.
Szczylik et al. (1991) Science 253:562-565.

Affiliated with

Also associated with

Rating

Antisense oligonucleotides targeting cooperating oncogenes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotides targeting cooperating oncogenes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides targeting cooperating oncogenes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-53381